<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1605">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04350580</url>
  </required_header>
  <id_info>
    <org_study_id>D20-P013</org_study_id>
    <secondary_id>2020-001570-30</secondary_id>
    <nct_id>NCT04350580</nct_id>
  </id_info>
  <brief_title>Polyvalent Immunoglobulin in COVID-19 Related ARds</brief_title>
  <acronym>ICAR</acronym>
  <official_title>Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier St Anne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Hospitalier Universitaire Paris psychiatrie &amp; neurosciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier St Anne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      As of 30/03/2020, 715600 people have been infected with COVID-19 worldwide and 35500 people
      died, essentially due to respiratory distress syndrome (ARDS) complicated in 25% of the with
      acute renal failure. No specific pharmacological treatment is available yet. The lung lesions
      are related to both the viral infection and to an intense inflammatory reaction. Because of
      it's action, as an immunomodulatory agent that can attenuate the inflammatory reaction and
      also strengthen the antiviral response, it is proposed to evaluate the effectiveness and
      safety of intravenous immunoglobulin administration (IGIV) in patients developing ARDS
      post-SARS-CoV2. IGIV modulates immunity, and this effect results in a decrease of
      pro-inflammatory activity, key factor in the ARDS related to the COVID-19. It should be noted
      that IGIV is part of the treatments in various diseases such as autoimmune and inflammatory
      diffuse interstitial lung diseases. In addition, they have been beneficial in the
      post-influenza ARDS but also have been in 3 cases of post-SARS-CoV2 ARDS. IGIV is a treatment
      option because it is well tolerated, especially concerning the kidney. These elements
      encourage a placebo-controlled trial testing the benefit of IGIV in ARDS post-SARS-CoV2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As of 30/03/2020, 715600 people have been infected with COVID-19 worldwide and 35 500 people
      have died, mainly from acute respiratory distress syndrome (ARDS) complicated in 25% of cases
      with acute renal failure. No specific pharmacological treatment is available yet. Pulmonary
      lesions in these patients are related to both viral infection and an inflammatory reaction.
      Patients admitted to intensive care have an important inflammatory response and increased
      plasma concentrations of IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and TNFα.

      In the blood, the number of peripheral CD4 and CD8 T cells appears to be significantly
      reduced, while their status is hyperactivated. This is evidenced by immunoreactive
      cytometrics for HLA-DR (CD4 3-47%) and CD38 (CD8 39-4%) or by an increase in the proportion
      of highly pro-inflammatory Th 17 CCR6+ lymphocytes. In addition, CD8 T cells would exhibit a
      highly cytotoxic profile characterized by high concentrations of cytotoxic granules,
      perforin+, granulysin+ or double positive, suggesting associated complement activation.
      Because of their immunomodulatory action, which can attenuate the inflammatory response; and
      also strengthen the anti-viral defence, it is proposed to evaluate the efficacy and safety of
      intravenous immunoglobulin (IGIV) administration in patients developing post-SARS-CoV2 ARDS.

      IGIV modifies cell function of dendritic cells, cytokine and chemokine networks and
      T-lymphocytes, resulting in the proliferation of regulatory T cells to regulate the activity
      of T lymphocytes CD4 or CD8. The action of IGIV induces an activation more particularly of
      lymphocytes T regulators that could modulate the effects of the lymphocyte populations
      described in the study by Xu et al during COVID-19. In addition, IGIV modulate humoral
      acquired immunity, through their effect on the idiotypic network and antibody production.
      They also act on innate immunity, through antigen neutralization and modulation of phagocytic
      cells. These effects result in a decrease in the production of pro-inflammatory cytokines and
      complement activation, key factors in post-SARS-CoV2 ARDS.

      IGIV is part of the treatment for a variety of autoimmune and inflammatory diseases. The
      standard IGIV as well as polyclonal IGIV significantly reduced mortality in patients with
      septic shock and in Kawasaki disease, which is post-viral vasculitis of the child. In
      addition, they would not only be beneficial in post-influenza ARDS, but also would also in 3
      cases of post-SARS-CoV2 ARDS. IVIG is a treatment option because it is well tolerated,
      especially regarding renal function.

      These factors are encouraging to quickly conduct a multicentre randomized placebo-controlled
      trial testing the benefit of IGIV in post-SARS-CoV2 ARDS.

      We hypothesize that the number of days without invasive mechanical ventilation (IMV) is 10
      days in the placebo group and 15 days in the experimental group with a standard deviation of
      6 days, considering a mortality of 50% and 40% in the placebo and experimental groups
      respectively (26, 27). The number of days without IMV in the placebo group is (50% x 10 D) +
      (50% x 0 D) or 5 D on average, and following the same calculation for the experimental group
      of (60% x 15 D) + (40% x 0 D) or 9 D.

      Therefore, a mean value of 5 days without ventilation in the placebo group versus 9 in the
      experimental group is assumed, and the 6-day standard deviation is assumed to be stable.
      Given the uncertainty regarding the assumption of normality of distributions, the
      non-parametric Wilcoxon-Mann-Whitney test (U-test) was used for the estimation of the sample
      size. Considering a bilateral alpha risk of 5% and a power of 90% and an effect size of 0.6,
      the number of subjects to be included is 138 patients, 69 in each arm.

      The primary and secondary analyses will be stratified by age categories, sex and other
      clinically relevant factors (comorbidities). Demographic characteristics and parameters
      identified at enrolment will be summarized using descriptive statistical methods.

      Demographic summaries will include gender, race/ethnicity, and age. For demographic and
      categorical background characteristics, a Cochran-Mantel-Haenszel test will be used to
      compare treatment groups. For continuous demographic and baseline characteristics, a Wilcoxon
      test will be used to compare treatment groups.

      The number of days without mechanical ventilation will be presented as a mean with standard
      deviation. The groups will be analyzed in terms of intention to treat and the difference
      between the two groups will be analyzed by a non-parametric test of comparison of means,
      stratified for the primary endpoint. The point estimate of the difference between treatments
      and the associated 95% confidence interval will be provided.

      A regression model for censored data (Cox model) will explore prognostic factors. The IGIV
      immunological and pathological related efficacy endpoints will also be compared according to
      their distribution and analyzed using Student, Mann-Whitney and Fisher tests.

      Other variables will be presented as means and standard deviations or medians and
      interquartile ranges according to their distribution and analyzed by Student, Mann-Whitney
      and Fisher tests.

      Parameters that are measured on a time scale from randomization or start of administration
      will be compared between treatment groups using the Log-Rank test.

      The choice of statistical tests and multivariate models (parametric or non-parametric) will
      be made for each variable based on observed characteristics (normality of distributions and
      residuals, collinearity).

      The statistical analyses relating to the main objective will be carried out as intention to
      treat. Secondary analyses on the population per protocol may also be carried out.

      All tests will be bilateral with a significance threshold of 5%. The software used will be
      SPSS v26 (SPSS Inc., Chicago, IL, USA). An interim analysis will be performed after 50
      participants are enrolled and another after 100 inclusions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The participant will be randomized to either the group of treatment with IVIG or the placebo group. Participants in the treatment group will receive infusions of polyvalent immunoglobulins for 4 consecutive days. Participants in the placebo group will receive an equivalent volume of sodium chloride 0.9% for the same duration.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The double blinding will be provided by the hospital pharmacy of each establishment with the help of opaque sleeves to mask the product packaging and should be returned to the pharmacy when empty.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>28 days</time_frame>
    <description>Sum of the days the patient did not receive VM, but if death occurs before D28, the score is zero</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 and 90 days</time_frame>
    <description>Vital status at 28 and 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment Score</measure>
    <time_frame>Days 1, 3, 7, 14, 21 and 28</time_frame>
    <description>Used to determine the extent of a person's organ function or rate of failure, from 0 to 24, with severity increasing the higher the score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P/F ratio</measure>
    <time_frame>Days 1, 3, 7, 14, 21 and 28</time_frame>
    <description>Ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2 expressed as a fraction, not a percentage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung compliance</measure>
    <time_frame>Days 1, 3, 7, 14, 21 and 28</time_frame>
    <description>Measure of lung compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological score</measure>
    <time_frame>Days 1, 3, 7, 14, 21 and 28</time_frame>
    <description>Severity scoring of lung oedema on the chest radiograph</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological efficacy endpoints - C-reactive protein</measure>
    <time_frame>Days 1, 3, 7, 14, 21 and 28</time_frame>
    <description>Concentration in mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological efficacy endpoints - Procalcitonin</measure>
    <time_frame>Days 1, 3, 7, 14, 21 and 28</time_frame>
    <description>Concentration in microgram/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological profile</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Number of CD4 HLA-DR+ and CD38+, CD8 lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients using other treatments for COVID-19 related ARDS</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Use of corticosteroids, antiretroviral, chloroquine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of deep vein thrombosis or pulmonary embolism</measure>
    <time_frame>28 days</time_frame>
    <description>Diagnosis of deep vein thrombosis or pulmonary embolism through imaging exam (eg ultrasound and CT scan)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of mechanical ventilation, ventilatory weaning and curarisation</measure>
    <time_frame>28 days</time_frame>
    <description>Total time of mechanical ventilation, weaning and use of neuromuscular blockade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Disease: Improving Global Outcomes (KDIGO) score and need for dialysis</measure>
    <time_frame>28 days</time_frame>
    <description>Divided in 3 stages, with higher severity of kidney injury in higher stages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse event related to immunoglobulins</measure>
    <time_frame>28 days</time_frame>
    <description>Kidney failure, hypersensitivity with cutaneous or hemodynamic manifestations, aseptic meningitis, hemolytic anemia, leuko-neutropenia, transfusion related acute lung injury (TRALI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of critical illness neuromyopathy</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Medical research council sum score on awakening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of ventilator-acquired pneumonia</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Radiological and clinical context associated with a bacteriological sampling in culture of tracheal secretions, bronchiolar-alveolar lavage or a protected distal sampling</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Intervention - IGIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the intervention group will receive a 2g/Kg infusion of human immunoglobulin which should be started between 24 and 36 hours after the start of mechanical ventilation in 4 injections of 0.5 g/Kg over 4 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants of the placebo group will receive an equivalent volume of sodium chloride 0.9% for the same duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human immunoglobulin</intervention_name>
    <description>Human immunoglobulin 2g/kg over 4 days (0.5g/kg/d)</description>
    <arm_group_label>Intervention - IGIV</arm_group_label>
    <other_name>Clairyg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium chloride 0.9% in the same volume and over the same time as the immunoglobulin</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium chloride 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient in intensive care:

               1. Receiving invasive mechanical ventilation for less than 36 hours

               2. ARDS meeting the Berlin criteria

               3. PCR-proven SARS-CoV-2 infection

               4. Patient, family or deferred consent (emergency clause)

               5. Affiliation to a social security scheme (or exemption from affiliation)

        Exclusion Criteria:

          -  Allergy to polyvalent immunoglobulins

          -  Pregnant woman or minor patient

          -  Known IgA deficiency

          -  Patient with renal failure on admission defined by a 3 times baseline creatinine or
             creatinine &gt;354 micromol/L or a diuresis of less than 0.3 mL/Kg for 24 hours or anuria
             for 12 hours

          -  Participation in another interventional trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek Sharshar, MD, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Sainte Anne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aurélien Mazeraud, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Sainte Anne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélien Mazeraud, MD, PHD</last_name>
    <phone>0145658902</phone>
    <email>a.mazeraud@ghu-paris.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tarek Sharshar, MD, PHD</last_name>
    <phone>0145658902</phone>
    <email>t.sharshar@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Sud Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Slama Michel</last_name>
    </contact>
    <investigator>
      <last_name>Slama Michel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Asfar</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Asfar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de réanimation polyvalente, rond point de Girac</name>
      <address>
        <city>Angoulême</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schnell David</last_name>
    </contact>
    <investigator>
      <last_name>Schnell David</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Aulnay</name>
      <address>
        <city>Aulnay-sous-Bois</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Santoli</last_name>
    </contact>
    <investigator>
      <last_name>François Santoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Béthune</name>
      <address>
        <city>Beuvry</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Vinsonneau</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Vinsonneau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane Gaudry</last_name>
    </contact>
    <investigator>
      <last_name>Stéphane Gaudry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Chalons en champagne</name>
      <address>
        <city>Chalons en champagne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Chillet</last_name>
    </contact>
    <investigator>
      <last_name>Patrick Chillet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH-Nord-Ardennes</name>
      <address>
        <city>Charleville-Mézières</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Mateu</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Mateu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital d'instruction des armées Percy</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudnicki Stéphane</last_name>
    </contact>
    <investigator>
      <last_name>Rudnicki Stéphane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Dieppe</name>
      <address>
        <city>Dieppe</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Louis Declercq</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Louis Declercq</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Djillali Annane</last_name>
    </contact>
    <investigator>
      <last_name>Djillali Annane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Schwebel</last_name>
    </contact>
    <investigator>
      <last_name>Carole Schwebel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand hopital de l'est Francilien - site de Jossigny</name>
      <address>
        <city>Jossigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zarka Jonathan</last_name>
    </contact>
    <investigator>
      <last_name>Zarka Jonathan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie Martin</last_name>
    </contact>
    <investigator>
      <last_name>Aurélie Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pôle de Médecine intensive/réanimation Hôpital Salengro, CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Poissy Julien</last_name>
    </contact>
    <investigator>
      <last_name>Poissy Julien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Edouar Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Argaud</last_name>
    </contact>
    <investigator>
      <last_name>Laurent Argaud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse Novembre 2019</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mazard Tessa</last_name>
    </contact>
    <investigator>
      <last_name>Mazard Tessa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyril Goulenok</last_name>
    </contact>
    <investigator>
      <last_name>Cyril Goulenok</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Jacques Monod</name>
      <address>
        <city>Montivilliers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Lemaitre</last_name>
    </contact>
    <investigator>
      <last_name>Caroline Lemaitre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Intensive-Réanimation, CHU</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reignier Jean</last_name>
    </contact>
    <investigator>
      <last_name>Reignier Jean</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muller Grégoir</last_name>
    </contact>
    <investigator>
      <last_name>Muller Grégoir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sainte-Anne</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélien Mazeraud, MD PHD</last_name>
    </contact>
    <investigator>
      <last_name>Aurélien Mazeraud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lariboisiere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megarbane Bruno</last_name>
    </contact>
    <investigator>
      <last_name>Megarbane Bruno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pitié Salpétriere Service de réanimation chirurgicale</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Michel Constantin</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Michel Constantin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Garnier</last_name>
    </contact>
    <investigator>
      <last_name>Marc Garnier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation ophtalmologique Rotschild</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trouiller Pierre</last_name>
    </contact>
    <investigator>
      <last_name>Trouiller Pierre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Paris Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cédric Bruel</last_name>
    </contact>
    <investigator>
      <last_name>Cédric Bruel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Rohaut</last_name>
    </contact>
    <investigator>
      <last_name>Benjamin Rohaut</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Lamer</last_name>
    </contact>
    <investigator>
      <last_name>Christian Lamer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Robert Débré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Mourvillier</last_name>
    </contact>
    <investigator>
      <last_name>Bruno Mourvillier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Poissy</name>
      <address>
        <city>Saint-Germain-en-Laye</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Outin</last_name>
    </contact>
    <investigator>
      <last_name>Hervé Outin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalier Saint Vincent</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Braun</last_name>
    </contact>
    <investigator>
      <last_name>Thierry Braun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Pottecher</last_name>
    </contact>
    <investigator>
      <last_name>Julien Pottecher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Tarbes</name>
      <address>
        <city>Tarbes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madeux Benjamin</last_name>
    </contact>
    <investigator>
      <last_name>Madeux Benjamin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche-Comté</name>
      <address>
        <city>Trévenans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moneger Guy</last_name>
    </contact>
    <investigator>
      <last_name>Moneger Guy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien Lambiotte</last_name>
    </contact>
    <investigator>
      <last_name>Fabien Lambiotte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Nancy - Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Losser Marie-Reine</last_name>
    </contact>
    <investigator>
      <last_name>Losser Marie-Reine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Vannes</name>
      <address>
        <city>Vannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agathe Delbove</last_name>
    </contact>
    <investigator>
      <last_name>Agathe Delbove</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annabelle Stoclin</last_name>
    </contact>
    <investigator>
      <last_name>Annabelle Stoclin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Etampes</name>
      <address>
        <city>Étampes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shidasp Siami</last_name>
    </contact>
    <investigator>
      <last_name>Shidasp Siami</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18. Erratum in: Lancet Respir Med. 2020 Feb 25;:.</citation>
    <PMID>32085846</PMID>
  </reference>
  <reference>
    <citation>Chaigne B, Mouthon L. Mechanisms of action of intravenous immunoglobulin. Transfus Apher Sci. 2017 Feb;56(1):45-49. doi: 10.1016/j.transci.2016.12.017. Epub 2016 Dec 30. Review.</citation>
    <PMID>28161150</PMID>
  </reference>
  <reference>
    <citation>Arish N, Eldor R, Fellig Y, Bogot N, Laxer U, Izhar U, Rokach A. Lymphocytic interstitial pneumonia associated with common variable immunodeficiency resolved with intravenous immunoglobulins. Thorax. 2006 Dec;61(12):1096-7.</citation>
    <PMID>17114373</PMID>
  </reference>
  <reference>
    <citation>Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, Roman K, Dua JS, Flynn I. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003;(4):CD004000. Review.</citation>
    <PMID>14584002</PMID>
  </reference>
  <reference>
    <citation>Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013 Sep 16;(9):CD001090. doi: 10.1002/14651858.CD001090.pub2. Review.</citation>
    <PMID>24043371</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute respiratory distress syndrome</keyword>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Immunoglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

